RxSight stock gains ahead of Stifel meeting, investors wait for signs of turnaround
RxSight Inc. trades higher Thursday morning. The ophthalmic device stock finished at $6.160 on Wednesday, a gain of 3.53%. Even with that bounce, shares are down 40.88% year-to-date. Execution is the key test in the near term, not launching something new. RxSight said management will join a fireside chat at the Stifel 2026 Virtual Ophthalmology Forum on May 26. The event gives investors a set time to see if the company’s sales reset has momentum.